Newsroom - Alvotech - Better Access Better Lives

Skip Navigation

Alvotech

Latest news

22 October 2025

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

06 October 2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

22 September 2025

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

Media Contact

Benedikt Stefansson

Director of Investor Relations and Global Communications

Phone +354 422 4500

Connect on Linkedin

Media Gallery

Download center for company logos and images

Alvotech 2022. All rights reserved.